1-acetyl-4-(4-{methyl-[(2-o-tolylamino-benzoxazol-6-yl)-acetyl]-amino}-phenyl)-pyrrolidine-3-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1-acetyl-4-(4-{methyl-[(2-o-tolylamino-benzoxazol-6-yl)-acetyl]-amino}-phenyl)-pyrrolidine-3-carboxylic acid
• 英文别名: 1-Acetyl-4-[4-[methyl-[2-[2-(2-methylanilino)-1,3-benzoxazol-6-yl]acetyl]amino]phenyl]pyrrolidine-3-carboxylic acid
• 化学式: C₃₀H₃₀N₄O₅
• 分子量: 526.592
• InChiKey: GIVRUHWFDYWCGB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  39
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  116
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Substituted pyrrolidines
  申请人：——

  公开号：US20020094994A1

  公开（公告）日：2002-07-18

  The invention is directed to physiologically active compounds of formula (I): 1 wherein one of A 1 , A 2 and A 3 represents NR 2 and the others represent C(R 3 )(R 4 ); R 1 represents R 5 Z 1 —Het- or R 6 N(R 7 )—C(═O)—NH—Ar 2 —; Ar 1 represents aryldiyl or heteroaryldiyl; L 1 represents a —R 12 -R 13 — linkage (where R 12 is a direct bond or an alkylene chain, an alkenylene chain or an alkynylene chain and R 13 is a direct bond, cycloalkylene, heterocycloalkylene, aryldiyl, heteroaryldiyl, —C(═Z 3 )—NR 11 —, —NR 11 —C(═Z 3 )—, —Z 3 —, —C(═O)—, —C(═NOR 11 )—, —NR 11 —, —NR 11 —C(═Z 3 )—NR 11 —, —SO 2 —NR 11 —, —NR —SO 2 —, —O—C(═O)—, —C(═O)—O—, —NR 11 —C(═O)—O— or —O—C(═O)—NR 11 —); and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs. Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA4 (&agr;4&bgr;1).

  该发明涉及式(I)的生理活性化合物：其中A1、A2和A3中的一个代表NR2，其他代表C(R3)(R4)；R1代表R5Z1—Het-或R6N(R7)—C(═O)—NH—Ar2—；Ar1代表芳基二基或杂芳基二基；L1代表一个—R12-R13—连接（其中R12是直接键或烷基链、烯基链或炔基链，R13是直接键、环烷基、杂环烷基、芳基二基、杂芳基二基、—C(═Z3)—NR11—、—NR11—C(═Z3)—、—Z3—、—C(═O)—、—C(═NOR11)—、—NR11—、—NR11—C(═Z3)—NR11—、—SO2—NR11—、—NR—SO2—、—O—C(═O)—、—C(═O)—O—、—NR11—C(═O)—O—或—O—C(═O)—NR11—)）；以及它们的前药、这些化合物及其前药的药学上可接受的盐和溶剂化合物。这些化合物具有有价值的药物特性，特别是调节VCAM-1和纤维连接蛋白与整合素VLA4（α4β1）相互作用的能力。
• SUBSTITUTED PYRROLIDINES AS CELL ADHESION INHIBITORS
  申请人：Aventis Pharma Limited

  公开号：EP1189883A2

  公开（公告）日：2002-03-27
• US6548533B2
  申请人：——

  公开号：US6548533B2

  公开（公告）日：2003-04-15
• [EN] SUBSTITUTED PYRROLIDINES<br/>[FR] PYRROLIDINES SUBSTITUEES
  申请人：AVENTIS PHARMA LTD

  公开号：WO2000068195A2

  公开（公告）日：2000-11-16

  The invention is directed to physiologically active compounds of Formula (I): wherein one of A?1, A2 and A3¿ represents NR2 and the others represent C(R?3)(R4); R1¿ represents R5Z1-Het- or R6N(R7)-C(=O)-NH-Ar2-; Ar1 represents aryldiyl or heteroaryldiyl; L1 represents a -R12-R13-linkage (where R12 is a direct bond or an alkylene chain, an alkenylene chain or an alkynylene chain and R13 is a direct bond, cycloalkylene, heterocycloalkylene, aryldiyl, heteroaryldiyl, -C(=Z?3)-NR11-,-NR11-C(=Z3)-, -Z3¿-,-C(=O)-, -C(=NOR?11)-, -NR11-, -NR11-C(=Z3)-NR11¿-, -SO¿2?-NR?11-, -NR11-SO¿2-, -O-C(=O)-, -C(=O)-O-, -NR11-C(=O)-O- or -O-C(=O)-NR11-); and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs. Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 (α4β1).